CEREBROSPINAL FLUID PENETRATION OF PEXIDARTINIB (PLX3397), A CSF1R INHIBITOR, IN A NONHUMAN PRIMATE MODEL

被引：0
|
作者：
Odabas, Arman [1 ]
McCully, Cynthia M. Lester [1 ]
Cruz, Rafael [1 ]
Figg, William D. [1 ]
Glod, John [1 ]
Rymar, Andrey [2 ]
Peer, Cody [1 ]
Warren, Katherine E. [1 ]
机构：
[1] NIH, Bldg 10, Bethesda, MD 20892 USA
[2] Plexxikon Inc, Berkeley, CA USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PHRM-03
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [21] Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib
    Priya S. Shankarappa
    Cody J. Peer
    Arman Odabas
    Cynthia L. McCully
    Rafael C. Garcia
    William D. Figg
    Katherine E. Warren
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 1003 - 1007
  • [22] Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib
    Shankarappa, Priya S.
    Peer, Cody J.
    Odabas, Arman
    McCully, Cynthia L.
    Garcia, Rafael C.
    Figg, William D.
    Warren, Katherine E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 1003 - 1007
  • [23] CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial
    Moskowitz, Craig H.
    Younes, Anas
    de Vos, Sven
    Bociek, R. Gregory
    Gordon, Leo I.
    Witzig, Thomas E.
    Gascoyne, Randy D.
    West, Brian
    Nolop, Keith
    Steidl, Christian
    BLOOD, 2012, 120 (21)
  • [24] Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
    Thongchot, Suyanee
    Duangkaew, Supani
    Yotchai, Wasan
    Maungsomboon, Sorranart
    Phimolsarnti, Rapin
    Asavamongkolkul, Apichat
    Thuwajit, Peti
    Thuwajit, Chanitra
    Chandhanayingyong, Chandhanarat
    HUMAN CELL, 2023, 36 (01) : 456 - 467
  • [25] Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
    Suyanee Thongchot
    Supani Duangkaew
    Wasan Yotchai
    Sorranart Maungsomboon
    Rapin Phimolsarnti
    Apichat Asavamongkolkul
    Peti Thuwajit
    Chanitra Thuwajit
    Chandhanarat Chandhanayingyong
    Human Cell, 2023, 36 : 456 - 467
  • [26] CSF1R Kinase Inhibitor Pexidartinib Disrupts Bile Acid Homeostasis in Mice
    Li, Feng
    Qin, Xuan
    Chen, Si
    Zhou, Shenzhi
    Hakenjos, John M.
    Guo, Lei
    Mackenzie, Kevin R.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (03):
  • [27] Phase 1/2a study of double immune suppression blockade by combining a CSF1 R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors.
    Patnaik, Amita
    Eisenberg, Peter D.
    Sachdev, Jasgit C.
    Weise, Amy M.
    Tse, Archie N.
    Hutchinson, Marguerite
    Aromin, Ireene
    West, Brian
    Tong, Sandra
    Ribas, Antoni
    Hu-Lieskovan, Siwen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex™) in a nonhuman primate model
    Widemann, BC
    Balis, FM
    Godwin, KS
    McCully, C
    Adamson, PC
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) : 439 - 443
  • [29] The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (TomudexTM) in a nonhuman primate model
    Brigitte C. Widemann
    Frank M. Balis
    Karen S. Godwin
    Cindy McCully
    Peter C. Adamson
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 439 - 443
  • [30] Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model
    Berg, SL
    Reid, J
    Godwin, K
    Murry, DJ
    Poplack, DG
    Balis, FM
    Ames, MM
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1999, 21 (01) : 26 - 30
12345